Yan Moore

502 total citations
31 papers, 221 citations indexed

About

Yan Moore is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Yan Moore has authored 31 papers receiving a total of 221 indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Oncology, 11 papers in Molecular Biology and 6 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Yan Moore's work include Lung Cancer Research Studies (14 papers), Cancer therapeutics and mechanisms (10 papers) and Cancer Treatment and Pharmacology (8 papers). Yan Moore is often cited by papers focused on Lung Cancer Research Studies (14 papers), Cancer therapeutics and mechanisms (10 papers) and Cancer Treatment and Pharmacology (8 papers). Yan Moore collaborates with scholars based in United States, Spain and France. Yan Moore's co-authors include Dan Theodorescu, Matthew J. Bassignani, Fiona Maxwell, Bruce Belanger, Tiffany Wang, Bin Zhang, Tanios Bekaii‐Saab, Teresa Macarulla, Zev A. Wainberg and Kabir Mody and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Cancer Research.

In The Last Decade

Yan Moore

31 papers receiving 218 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Yan Moore United States	9	112	98	89	38	36	31	221
Stephanie O. Dudzinski United States	5	126 1.1×	68 0.7×	46 0.5×	48 1.3×	24 0.7×	12	268
Yiran Cai China	11	119 1.1×	121 1.2×	167 1.9×	78 2.1×	16 0.4×	21	314
Connor Lynch United States	5	81 0.7×	44 0.4×	65 0.7×	45 1.2×	23 0.6×	14	213
Caifeng Zou China	8	138 1.2×	142 1.4×	78 0.9×	112 2.9×	18 0.5×	14	302
J. L. Marshall United States	6	141 1.3×	32 0.3×	48 0.5×	15 0.4×	29 0.8×	10	179
Daniel J. Craig United States	8	96 0.9×	51 0.5×	50 0.6×	36 0.9×	15 0.4×	13	191
Xiangyan Qiu China	3	298 2.7×	72 0.7×	41 0.5×	23 0.6×	19 0.5×	6	453
Matthew S. Strand United States	5	73 0.7×	68 0.7×	39 0.4×	28 0.7×	8 0.2×	11	166
Christoforos Astaras Switzerland	6	129 1.2×	68 0.7×	69 0.8×	49 1.3×	24 0.7×	11	207

Countries citing papers authored by Yan Moore

Since Specialization

Citations

This map shows the geographic impact of Yan Moore's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yan Moore with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yan Moore more than expected).

Fields of papers citing papers by Yan Moore

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yan Moore. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yan Moore. The network helps show where Yan Moore may publish in the future.

Co-authorship network of co-authors of Yan Moore

This figure shows the co-authorship network connecting the top 25 collaborators of Yan Moore. A scholar is included among the top collaborators of Yan Moore based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yan Moore. Yan Moore is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Wu, Tinghui, et al.. (2023). A phase 1/2 open-label study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of OTX-2002 as a single agent and in combination with standard of care in patients with hepatocellular carcinoma and other solid tumor types known for association with the MYC oncogene (MYCHELANGELO I).. Journal of Clinical Oncology. 41(4_suppl). TPS627–TPS627. 8 indexed citations

Spigel, David R., Luis Paz‐Ares, Yuanbin Chen, et al.. (2021). MO01.39 Liposomal Irinotecan in Adults with Small Cell Lung Cancer who Progressed on Platinum-Based Therapy: Subgroup Analyses by Platinum Sensitivity. Journal of Thoracic Oncology. 16(1). S32–S32. 2 indexed citations

Yap, Timothy A., Ecaterina E. Dumbrava, Jordi Rodón, et al.. (2021). First-in-human biomarker-driven phase I trial of the potent and selective glutaminase-1 (GLS1) inhibitor IACS-6274 (IPN60090) in patients (pts) with molecularly selected advanced solid tumors.. Journal of Clinical Oncology. 39(15_suppl). 3001–3001. 11 indexed citations

Paz‐Ares, Luis, David R. Spigel, Yuanbin Chen, et al.. (2021). FP10.04 RESILIENT Part 1: Safety and Efficacy of Second-Line Liposomal Irinotecan in Patients with Small Cell Lung Cancer. Journal of Thoracic Oncology. 16(3). S216–S216. 1 indexed citations

Wainberg, Zev A., Tanios Bekaii‐Saab, Patrick M. Boland, et al.. (2021). First-line liposomal irinotecan with oxaliplatin, 5-fluorouracil and leucovorin (NALIRIFOX) in pancreatic ductal adenocarcinoma: A phase I/II study. European Journal of Cancer. 151. 14–24. 31 indexed citations

Ponce, Santiago, Karl Brendel, David R. Spigel, et al.. (2020). 1793P RESILIENT part 1: Pharmacokinetics of second-line (2L) liposomal irinotecan in patients with small cell lung cancer (SCLC). Annals of Oncology. 31. S1038–S1039. 1 indexed citations

Sachdev, Jasgit C., Pamela N. Münster, Donald W. Northfelt, et al.. (2020). Phase I study of liposomal irinotecan in patients with metastatic breast cancer: findings from the expansion phase. Breast Cancer Research and Treatment. 185(3). 759–771. 33 indexed citations

Dean, Andrew, Tanios Bekaii‐Saab, Patrick M. Boland, et al.. (2020). 191P First-line liposomal irinotecan + 5 fluorouracil/leucovorin + oxaliplatin in patients with pancreatic ductal adenocarcinoma: Results from a phase I/II study. Annals of Oncology. 31. S1313–S1314. 1 indexed citations

Wainberg, Zev A., Tanios Bekaii‐Saab, Patrick M. Boland, et al.. (2020). LBA-1 First-line liposomal irinotecan + 5 fluorouracil/leucovorin + oxaliplatin in patients with pancreatic ductal adenocarcinoma: Long-term follow-up results from a phase 1/2 study. Annals of Oncology. 31. S241–S241. 3 indexed citations

10.

Paz‐Ares, Luis, David R. Spigel, Yuanbin Chen, et al.. (2020). RESILIENT part II: an open-label, randomized, phase III study of liposomal irinotecan injection in patients with small-cell lung cancer who have progressed with platinum-based first-line therapy.. Journal of Clinical Oncology. 38(15_suppl). TPS9081–TPS9081. 3 indexed citations

11.

Wainberg, Zev A., Patrick M. Boland, Christopher H. Lieu, et al.. (2019). A phase 1/2, open-label, dose-expansion study of liposomal irinotecan (nal-IRI) plus 5-fluorouracil/leucovorin (5-FU/LV) and oxaliplatin (OX) in patients with previously untreated metastatic pancreatic cancer. Annals of Oncology. 30. iv123–iv123. 3 indexed citations

12.

Rodríguez, Luis Paz-Ares, David R. Spigel, Yuanbin Chen, et al.. (2019). OA03.03 Initial Efficacy and Safety Results of Irinotecan Liposome Injection (nal-IRI) in Patients with Small Cell Lung Cancer. Journal of Thoracic Oncology. 14(10). S211–S212. 2 indexed citations

13.

Dayyani, Farshid, Patrick M. Boland, Andrew Dean, et al.. (2019). Abstract B14: CA 19-9 levels in patients with metastatic pancreatic adenocarcinoma receiving first-line therapy with liposomal irinotecan plus 5-fluorouracil/leucovorin and oxaliplatin (NAPOX). Cancer Research. 79(24_Supplement). B14–B14. 1 indexed citations

14.

Macarulla, Teresa, Karl Brendel, Christopher H. Lieu, et al.. (2019). Integrated population pharmacokinetic modelling of liposomal irinotecan in patients with various tumour types, including untreated metastatic pancreatic cancer (mPC). Annals of Oncology. 30. v263–v263. 2 indexed citations

15.

Anders, Carey K., Pamela N. Münster, Donald W. Northfelt, et al.. (2019). TRLS-06. PHASE 1 EXPANSION STUDY OF IRINOTECAN LIPOSOME INJECTION (nal-IRI) IN PATIENTS WITH METASTATIC BREAST CANCER (mBC): FINDINGS FROM THE COHORT WITH ACTIVE BRAIN METASTASIS (BM). Neuro-Oncology Advances. 1(Supplement_1). i9–i9. 1 indexed citations

16.

Halachmi, Sarel, Ilan Leibovitch, Amnon Zisman, et al.. (2018). Phase II trial of BC-819 intravesical gene therapy in combination with BCG in patients with non-muscle invasive bladder cancer (NMIBC).. Journal of Clinical Oncology. 36(6_suppl). 499–499. 13 indexed citations

17.

Taı̈eb, Julien, Roberto Bordonaro, Katia Bencardino, et al.. (2014). Quality of Life (Qol) on the Aflibercept/Folfiri Regimen: 4Th Interim Analysis of the Global Aflibercept Safety and Health-Related Qol Program. Annals of Oncology. 25. iv180–iv180. 1 indexed citations

18.

Taı̈eb, Julien, Roberto Bordonaro, Salvatore Siena, et al.. (2014). Quality of life maintained on the ziv-aflibercept/FOLFIRI regimen: Third interim analysis of the global aflibercept safety and HR-QOL program.. Journal of Clinical Oncology. 32(15_suppl). e14560–e14560. 1 indexed citations

19.

Pivot, Xavier, John Hackmann, Alexey Manikhas, et al.. (2011). P4-17-03: Incidence Rate of Asymptomatic Brain Metastases in Patients with HER2+ Metastatic Breast Cancer Screened for EGF111438/CEREBEL Study.. Cancer Research. 71(24_Supplement). P4–17. 3 indexed citations

20.

Bassignani, Matthew J., et al.. (2004). PILOT EXPERIENCE WITH REAL-TIME ULTRASOUND GUIDED PERCUTANEOUS RENAL MASS CRYOABLATION. The Journal of Urology. 171(4). 1620–1623. 49 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact